Company news
Rebus Hldgs Inc. news in 2016
Rebus Hldgs Inc.'s news releases, calls and decks from 2016, newest first.
UPDATE -- Inspyr Announces Private Placement of $1.0 Million
December 12, 2016
Inspyr Broadens Intellectual Property Portfolio with New Patent Issued on Methods for Producing Cancer Compounds
October 20, 2016
Inspyr Therapeutics Appoints Richard Buller, M.D., Ph.D. to Board of Directors
October 13, 2016
Inspyr Therapeutics Appoints Claire Thom, Pharm.D. to Board of Directors
October 12, 2016
Inspyr Therapeutics Strengthens Clinical Development Capabilities with Appointment of Michael Elliott as Vice President of Clinical Operations
October 11, 2016
Phyton Biotech Achieves Manufacturing Milestone with Thapsigargin, the Active Agent in Mipsagargin
August 22, 2016
Inspyr Therapeutics Announces the Initiation of a Phase 2 Clinical Trial of Mipsagargin for Newly Diagnosed Prostate Cancer Patients
August 17, 2016
Inspyr Therapeutics Appoints Ronald Shazer, M.D., as Senior Vice President and Chief Medical Officer
August 8, 2016
Inspyr Therapeutics Appoints Christopher Lowe Chief Executive Officer and Director
August 4, 2016
GenSpera Announces Name Change to Inspyr Therapeutics
August 1, 2016
GenSpera Announces Management Changes
March 22, 2016
GenSpera Engages FLG Partners LLC and Partner Chris Lowe for Strategic Business Advisory Services
March 11, 2016
GenSpera Issues Letter to Stockholders
January 6, 2016